Announcements

Seminar in Medine, 15.12.2017 , Fatih Selšukbiricik, M.D.

Author: KUSOM
Time: 15:00
Location: MED 176

KOÇ UNIVERSITY

SCHOOL OF MEDICINE

 

 

SEMINAR IN MEDICINE
Friday, December 15
th, 2017

******************************************************************

Speaker           : Fatih Selçukbiricik, M.D. /Koc University Hospital, Department of Oncology 

 Title                :A NOVEL BIOMARKER FOR ANTIANGIOGENIC THERAPY IN ONCOLOGY

Time               : 15:00 (Refresment will served at 14:45)
Place              : MED 176

TelePresence  :  AH Dean's Room / KUH 9th Meeting Room

********************************************************************

 

 

A NOVEL BIOMARKER FOR ANTIANGIOGENIC THERAPY IN ONCOLOGY

Recently, biomarkers in medicine have gained comprehensive scientific and clinical interest to predict outcome better and to evaluate the effectiveness of chemotherapy. A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. Vascular endothelial growth factor (VEGF) is an important marker on tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody which binds to VEGF and prevents the binding of VEGF with its receptors. In cancer tissues, increased expression of VEGF is associated with increased microvascular density, tumor growth, metastasis, and a poor prognosis. Bevacizumab damage to microcirculation and leads to hypoxia via VEGF inhibition. Due to impaired microcirculation in tumor and hypoxia, an increase in serum uric acid level might be observed.  

Uric acid may cause impairment in microcirculation, an increase in inflammation, oxidative stress and a decrease in nitric oxide. With this background in mind, we tested the predictive value of uric acid change on evaluating the treatment efficacy in metastatic colorectal cancer patients who received bevacizumab of which is vascularisation inhibitor. We showed for the first time in the literature that significant increases of serum uric acid in patients with metastatic colorectal cancer after chemotherapy with bevacizumab related with long-term survival compared to whose serum uric acid were not increased after bevacizumab. As a conclusion, an increase in serum uric acid level after antiangionesis therapy might be a novel promising marker for predicting outcome in patients with metastatic colorectal cancer.